Evaluation of In Vitro Equivalence of Commonly Available Generic Brands of Amlodipine Tablets in Saudi Arabia Under Biowaiver Conditions

Asim Najmi¹, Mohammed Al Bratty³, Bassam Abdullah Al-Bassam¹, Rami Ali Aseri³, Turki Suliman Wadani³, Abdulrahman Ibrahim Al-Muntashiri¹, Hassan A. Alhazmi¹,², Muhammad H. Sultan³, and Sadique A. Javed¹*¹

¹Department of Pharmaceutical Chemistry, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.
²Substance Abuse and Toxicology Research Centre, Jazan University, Jazan, Saudi Arabia.
³Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia.

*Corresponding author

e-mail: sajaved@jazanu.edu.sa; sadique.javed1980@gmail.com

ABSTRACT

When a medicine is not able to treat the disease for which it was intended, as in case of substandard and falsified drug products, it may prolong the disease and in worst scenario, the patient may die because of the untreated illness or the product itself. To ensure the quality and safety of medicine, WHO recommends timely evaluation of pharmaceutical quality. The present study is an attempt to evaluate the pharmaceutical properties and in vitro drug release of four generic brands and one innovator product (Norvasc) of amlodipine tablets (5 mg) according to USP and WHO guidelines. The products passed the compendial specifications of weight variation (< 5% deviation), friability (< 1% weight loss), and assay (90–110% of labeled amount). The tablets were fast-disintegrating, as complete disintegration observed in 1.20–1.64 min. The dissolution profiles of the generic products were equivalent to the innovator brand in pH 1.2 HCl and acetate buffer (pH 4.5) without statistical treatment (≥ 85% release in 15 min). In phosphate buffer (pH 6.8), ≥ 85% of drug dissolved in 30 min and in vitro equivalence was established by calculating the difference factor (f₁ < 15), similarity factor (f₂ > 50), and dissolution efficiency (± 10%). The tested brands met WHO BCS-based biowaiver criteria for in vitro dissolution testing, which ensured their pharmaceutical and therapeutic equivalence without in vivo screening and interchangeability with the innovator product.

KEYWORDS: In vitro equivalence, amlodipine tablets, biowaiver, drug release

INTRODUCTION

Generic pharmaceutical products are economical substitutes for innovator brands, being manufactured and marketed with different names after the end of the exclusive market rights held by the innovator company. Generic medicines must be biopharmaceutically equivalent to the innovator product to obtain the market authorization (1). The use of generic formulations is encouraged by the World Health Organization (WHO) as a measure to limit healthcare expenditures and improve access to medicine; however, cases have been identified where the quality of medications were compromised, especially those produced in middle- and low-income countries. Although, the economic requirement of price containment is undeniable, it is very important to safeguard the consumer’s health. Therefore, the innovator product can only be substituted with their generic counterparts when meeting the pharmaceutical quality.
Because drug-surfactant interactions are specific, careful choice of surfactant media is required to develop dissolution in vivo solubilization and sink conditions due to continuous intestinal absorption of TMX.

Bioequivalence studies involving in vitro and in vivo evaluation of immediate-release oral dosage forms mainly focus on dissolution testing. Absorption of drugs into systemic circulation is determined by dissolution of the drug product under physiological conditions, in vivo release of the drug molecule from formulation, and permeability of the drug through the gastrointestinal tract (GIT). Subsequent to the introduction of Biopharmaceutics Classification System (BCS) by the United States Food and Drug Administration (FDA) and WHO, in vitro drug release studies have emerged as a useful tool in assessing the quality of oral dosage forms (6, 7). According to this system, in vivo bioequivalence studies for the oral pharmaceutical formulations containing active ingredients from BCS Classes I and III could be waived and a comparative in vitro dissolution test will be enough for establishing equivalence of generic products with innovator formulations. The studies used to establish equivalence in place of in vivo evaluation are known as biowaiver studies. Consequently, in vivo performance of the oral pharmaceutical preparations can be predicted by the in vitro dissolution profile and hence, in vitro drug release testing is an acceptable substitute for approving bioequivalence of generic products with reference products (8–10).

Amlodipine belongs to dihydropyridinecarboxylic acid class of calcium channel blockers, which is a long-acting calcium antagonist with vascular selectivity and act through inhibition of transmembrane influx of Ca^{2+} into myocardium and vascular smooth muscles. Mainly, it is a long-acting antihypertensive agent, which is also used for treating vasospastic angina and coronary artery disease. Studies have also reported the antioxidative action of amlodipine, improving the status of oxidative stress in patients with essential hypertension (11, 12). Chemically, amlodipine is 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate (Fig. 1).
Amlodipine is a weakly basic drug (pKa 9.0 at 25 °C) that remains ionized within the GIT pH range. In the pH range of 1 to 6.8, the lowest water solubility of amlodipine at 37 °C is approximately 1 mg/mL, and water solubility is reported as 75.3 mg/mL at 25 °C; its logP value (n-octanol:water) is 2.96 (13–15). In Saudi Arabia, amlodipine is marketed as immediate-release tablet and capsule dosage forms and are available in the doses of 2.5, 5, and 10 mg. The 5-mg tablet of amlodipine is included in the WHO Model List of Essential Medicines for the treatment of hypertension. The dose-to-solubility ratio (D/S) for amlodipine at pH 1.2–6.8 is low (5 and 10 mL for 5 and 10 mg doses, respectively); therefore, according to WHO guidelines, amlodipine is considered to be ‘highly soluble’ (D/S ratio ≤ 250 mL) (16). According to WHO, a drug substance is regarded as ‘highly permeable’ when its absorption is 85% or more. Although, the absolute bioavailability of amlodipine is 60–65% (low), its permeability has been regarded as ‘high’, because of 90–95% excretion of the metabolite in urine (17). Consequently, on the basis of the solubility and permeability of amlodipine, WHO has kept it in BCS class I and therefore, equivalence of amlodipine tablets can be established through in vitro drug release testing under biowaiver conditions.

To the best of our knowledge, no such study has been performed on amlodipine tablets in the tested region. Therefore, the current study was undertaken to evaluate the quality of generic amlodipine tablets (5 mg) commercially available in Saudi Arabian markets through various quality control tests and compare the results with innovator product (Norvasc). As in vitro dissolution testing is the most important parameter to establish the equivalence of pharmaceutical oral formulation with innovator product and evaluate the product quality, greater emphasis was given on the in vitro dissolution testing under biowaiver conditions. Statistical analysis was performed for comparing the obtained drug-release profiles of the test products with the innovator; similarity and difference factors ($f_1$, $f_2$) and dissolution efficiency (DE) were evaluated.

The present study will provide scientific bases of the appropriateness of the tested products and substitution of these formulations with the innovator product to the patients, in case of cost-
concern and non-availability. Furthermore, we hope that the present study will help to minimize the prevalence of spurious and substandard medical products.

**MATERIALS AND METHODS**

**Chemicals, Samples, and Equipment**

Four generic brands of amlodipine tablets (5 mg) including Lofral (Lot. No.: 0B0200A, Exp. Date: 02/2020, Acino, Aesch, Switzerland), Vascodipine (Lot. No.: 17GQ93, Exp. Date: 11/2020, Riyadh Pharma, Riyadh, Saudi Arabia), Amlocard (Lot. No.: 2487, Exp. Date: 04/2021, Batterjee Pharma, Jeddah, Saudi Arabia) and Lodipam (Lot. No.: 10177, Exp. Date: 03/2021, Saudi Pharmaceutical Industries, Riyadh, Saudi Arabia) were purchased from local pharmacies in Jazan, Saudi Arabia, and were randomly assigned codes as AM-1 to AM-4. Due to non-availability, the innovator product (Norvasc, 5 mg, Lot. No.: 19102, Exp. Date: 04/2022, Pfizer, Egypt) was procured from Egypt and coded as ‘RP’. The samples were carefully examined for manufacturing and expiry dates and stored until further use. Pure amlodipine besylate (98.21%) was purchased from MedChemExpress, LLC (NJ, USA). Hydrochloric acid (HCl), acetic acid, and potassium dihydrogen orthophosphate were procured from Sigma-Aldrich (USA), and sodium acetate trihydrate, orthophosphoric acid, and methanol were obtained from HiMedia Laboratories (Mumbai, India). Deionized water (double distilled grade) was prepared in-house using a water purification system (Smart2Pure 3 UV/UF, Thermo Scientific, Sweden). All the samples and tablets were weighed on Mettler Toledo analytical balance (XP105DR, Switzerland). Absorbance of assay and dissolution sample were recorded using UV-visible spectrophotometer (UV-1800 240V, Shimadzu Corporation, Kyoto, Japan).

**Calibration/Performance Verification Tests of Dissolution Apparatus and UV-Spectrophotometer**

The calibration and performance verification test for the dissolution apparatus are performed every 6 months on a routine basis following the procedure recommended by United States Pharmacopoeia (USP). For the performance verification test, USP Prednisone Tablets RS is used, and the dissolution test is performed under the following dissolution conditions: medium: purified water after deaeration; volume: 900 mL; rotation speed: 50 rpm (for USP apparatus 2), time point: 30 min, temperature: 37 ± 0.5 °C. After manual sampling, the release of prednisone is determined by measuring the absorbance at 242 nm. Calibration of the UV-spectrophotometer is also performed on a routine basis by following the standard operating procedure. The calibration process is carried out to evaluate absorbance and wavelength controls, stary light limit, photometric linearity, resolution power, and appropriateness of baseline and sample cells.

**Evaluation of Physicochemical Properties**

All drug products (generic and innovator) were subjected to physical tests such as weight variation, friability, and disintegration time according to well-established protocols (4, 18). To determine the weight variation, 20 tablets of each generic and innovator product were weighed together as well as individually using electronic balance. The percentage of deviation in the weight of individual tablets from the average weight was calculated. Ten previously weighed
Role of Surfactants on Dissolution Behavior of Tamoxifen

Tuba Incecayir*, Seval Olgac, Duygu Yilmaz Usta, and Zeynep Safak Teksin

INTRODUCTION

For BCS Class II drugs, dissolution can be the rate-limiting step in drug absorption because drug-surfactant interactions are specific, and careful choice of surfactant media is required to develop dissolution tests for Biopharmaceutics Classification System (BCS) Class II drugs. The purpose of this study was to investigate the effects of cationic hexadecyltrimethylammonium bromide (CTAB) and nonionic surfactants (polysorbate 80) on the in vitro solubilization and sink conditions due to continuous intestinal absorption of TMX.

ABSTRACT

The introduction of tamoxifen (TMX) in the clinic has provided an additional tool for breast cancer treatment, tissue regression, and hormone balance control (1, 2). In the present study, in vitro dissolution technology was evaluated as the scientific approach to permit a waiver of in vivo bioavailability (BA) and/or bioequivalence (BE) studies as per U.S. FDA biowaiver guidelines by using the following dissolution media: 0.1 N HCl (pH 1.2), acetate buffer (pH 4.5), and phosphate buffer (pH 6.8). The in vivo performance during drug development, as well as for the establishment of biorelevance to forecast their in vivo performance, has been an important tool for waiving the regulatory requirement for in vivo BE test products were investigated to make a comparison (DT).

Determination of Amlodipine Content

The stock standard solution was prepared by taking an appropriate amount of amlodipine besylate and dissolving in a small amount of methanol by sonication. The volume was completed with 0.01 N HCl to achieve a concentration of 100 µg/mL. The calibration standards having the concentrations of 2, 5, 10, and 20 µg/mL were prepared in 0.01 N HCl in triplicate. The absorbance of all solutions was measured at 240 nm, and the calibration graph was constructed by plotting absorbance against concentrations. Regression analysis was performed, and the correlation coefficient was determined. The intra- and inter-day precision and accuracy of the method was established by analyzing three quality control (QC) samples at low (2 µg/mL), mid (10 µg/mL), and high (20 µg/mL) concentrations. The QC samples were prepared using amlodipine besylate tablet powder in triplicate. The accuracy was expressed by calculating the recovery of analyte, and the precision of the method was measured by the relative standard deviation percentage (%RSD) of the replicate analysis. Solution stability was determined by analyzing the working solution (10 µg/mL) after keeping aside at laboratory temperature (25 ± 2 ºC) for at least 12 h.

Assay analysis was performed to determine the amlodipine content in all generic products and the innovator product. Tablets were crushed to fine powder and weighed equivalent to 5 mg of amlodipine. The powder was sonicated in 5 mL of methanol for 10 min at room temperature. The volume was completed with 0.01 N HCl to 50 mL, and the solution was sonicated again for 5 min. The mixture was filtered through 0.45-µm nylon filter and further diluted with 0.01 N HCl to 10 µg/mL concentration. The absorbance of the solution was recorded at 240 nm using the UV-spectrophotometer in triplicate, and the amlodipine content was estimated using a standard calibration curve plotted between a range of concentrations of pure amlodipine solution versus their absorbances. The products were considered to satisfy acceptance criteria if assay results were within 90–110%.

In Vitro Dissolution Testing

The USP dissolution apparatus 2 (paddle type) was used to test in vitro drug release of four generic and one innovator tablet formulations. Dissolution tests were performed as per WHO and U.S. FDA biowaiver guidelines by using the following dissolution media: 0.1 N HCl (pH 1.2, simulated gastric fluid without enzyme, SGF), acetate buffer (pH 4.5), and phosphate buffer (pH 6.8, simulated intestinal fluid without enzyme, SIF) (6, 7). The procedure described in the USP-NF monograph for amlodipine immediate-release tablets was followed (5). The dissolution test was performed using 12 tablets in 500 mL of dissolution media. The apparatus operated at 75
rpm, and the temperature was maintained at 37 ± 2 °C throughout the tests. Sampling was done by withdrawing 5-mL aliquots from each vessel at 10, 15, 20, 30, 45, and 60 min followed by immediate replacement with fresh media to maintain the sink condition. The solutions filtered through 0.45-μm nylon filter and absorbance were measured by the UV-spectrophotometer against the respective dissolution medium as blank. The standard calibration graph was prepared between a range of drug concentrations, and their absorbance values were used to estimate the percentage of drug release.

The drug release curve was constructed by plotting the percentage of amlodipine dissolved against the sample withdrawal times. The U.S. FDA emphasizes comparing the drug-release profiles to establish equivalence between generic and reference products, therefore, a model-independent method was adopted, and the difference factor ($f_1$) and similarity factor ($f_2$) were calculated. The $f_1$ value represents the difference in the two drug release curves at each time point, and $f_2$ is used to estimate the similarity in drug release between the two drug dissolution profile curves. An $f_1$ value close to zero and $f_2$ value near 100% ensure the sameness of the drug release profiles of generic and innovator products. Generally, the drug release profile of a generic formulation is considered to be similar to the innovator product when $f_1$ is 0–15 and $f_2$ is 50–100 is obtained (19).

Release of amlodipine from generic tablets was compared with the innovator tablet according to biowaiver guidelines. Tablet formulations were considered to comply with the biowaiver conditions for drug product containing BCS Class 1 active pharmaceutical ingredient, if ≥ 85% the stated amount of the drug released in 30 min in pH 1.2, 4.5, and 6.8; furthermore, the drug release profiles of generic products in all dissolution media must be similar to that of the innovator formulation (i.e., $f_1 \leq 15$ and $f_2 \geq 50$). If the generic and innovator brands are both release more 85% in 15 min under the same dissolution conditions, then statistical comparison of the dissolution profiles is not required.

The drug release profiles of generic tablets were further evaluated by calculating DE values, which is the area under the drug release curve ($AUC_{0\rightarrow t}$) up to time point, $t$. The DE represents the area (%) of a rectangle ($R_{100}$) designated as 100% drug release up to the same time point (20). The drug release profile of the generic product is considered equivalent to the innovator product when the DE value is within ±10% of the innovator product (21).

Statistical Analysis

Statistical analyses of the assay, disintegration, and dissolution (30-min time point) data were performed by applying a one-way analysis of variance (ANOVA) followed by Tukey Kramer’s test using GraphPad InStat 3.1 (GraphPad Software). A $p$-value less than 0.05 was considered to be statistically significant. The mean, standard deviation (SD), and %RSD were calculated using Microsoft Excel 2010 (Microsoft Corporation). The data were presented as mean ± SD or mean ± %RSD, as applicable.

RESULTS AND DISCUSSION

The quality of pharmaceutical formulations is of utmost importance, as it is directly linked to the health of the consumer population. According to the findings of regulatory bodies such as WHO,
the quality of drug products is under remarkable risks, especially in poor and developing countries. As a consequence, regular monitoring of drug quality is required. Hence, in the present investigation, generic brand amlodipine tablets available in Saudi Arabia were subjected to quality evaluation and compared with the innovator brand.

**Physicochemical Evaluation**

The physicochemical evaluation results (weight variation, friability, assay, and disintegration time) are shown in Table 1.

*Table 1. Weight, Friability, Drug Content, and Disintegration Times of Generic (AM) and Innovator Brand Amlodipine Tablets*

<table>
<thead>
<tr>
<th>Products</th>
<th>Weight, mg (mean ± SD) (n = 20)</th>
<th>Friability, % (n = 10)</th>
<th>Drug Content, % (mean ± SD) (n = 3)</th>
<th>Disintegration time, min (mean ± SD) (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AM-1</td>
<td>200.29 ± 2.05</td>
<td>0.03</td>
<td>98.3 ± 0.75</td>
<td>1.20 ± 0.14</td>
</tr>
<tr>
<td>AM-2</td>
<td>205.09 ± 3.08</td>
<td>0.01</td>
<td>98.0 ± 0.58</td>
<td>1.37 ± 0.09</td>
</tr>
<tr>
<td>AM-3</td>
<td>201.42 ± 1.59</td>
<td>0.07</td>
<td>98.8 ± 0.95</td>
<td>1.64* ± 0.17</td>
</tr>
<tr>
<td>AM-4</td>
<td>212.33 ± 1.92</td>
<td>0.03</td>
<td>98.5 ± 1.16</td>
<td>1.34 ± 0.25</td>
</tr>
<tr>
<td>Innovator</td>
<td>201.49 ± 1.10</td>
<td>0.02</td>
<td>98.7 ± 0.65</td>
<td>1.25 ± 0.09</td>
</tr>
</tbody>
</table>

*Statistically significant difference (p < 0.05) between generic and innovator products for assay and disintegration data.

The tablet weight variations in all the tested brands were low (≤ 2.7% deviation) and complied with the specifications as for all the brands, none of the tablet weights deviated from average weight of the same brand by more than 5%. The highest weight variation was observed for generic product AM-2 (2.7%), and the lowest deviation in tablet weight was noticed for the innovator product (1.3%). Similarly, when subjected to friability test, the percentage of weight loss for the tablets were very low (≤ 0.07%), indicating that the tablets were sufficiently capable to withstand abrasion experienced during handling, packaging, and shipping for transportation. The friability test revealed that product AM-2 (0.01%) was least friable, and AM-3 (0.07%) had the highest friability. Consequently, the generic and innovator products were unlikely to lose particles from its surface during handling, keeping the general appearance and integrity of the tablets intact, and hence, have good consumer acceptability. According to official specifications, the tablet friability is considered to be acceptable if the product’s weight loss is < 1%.

The assay method was validated according to ICH guidelines (22). Regression analysis of the calibration curves exhibited a linear relationship over the concentration range of 2–20 µg/mL ($R^2 = 0.999$). The intra- and inter-day accuracy of the assay method was ascertained by the recovery of analyte within 100% ± 2%, and %RSD values less than 2% indicated good precision of the method. The analytical solution was found to be stable for at least 12 h at laboratory temperature (25 ± 2 °C) as the assay results were within 100% ± 2%.

Amlodipine content in the generic and innovator products was determined by UV-spectrophotometric analysis, and the assay calculation was performed using the standard calibration curve ($R^2 = 0.999$). The drug content of all tested products was within 90–110% of the labeled amlodipine amount, and therefore complied with official specifications (5). The highest percentage of amlodipine among the generic products was recorded in AM-3 (98.8% ±
0.95%), and the lowest assay result was observed in product AM-2 (98.0% ± 0.58%). The drug content in the innovator product was found to be 98.7% ± 0.65% of the label claim. Disintegration of tablets is considered to be the preliminary step towards dissolution; therefore, the disintegration time influences the drug release from an oral dosage form and subsequently affects bioavailability. The tested generic and innovator amlodipine tablets were fast disintegrating, as all the tablet brands completely disintegrated in 1.20–2.64 min and therefore passed this test according to the official specifications of immediate-release tablets (< 30 min). Among the generic products, the fastest disintegration was observed for AM-1 (1.20 ± 0.14 min), and the slowest disintegration time was recorded for AM-3 (1.64 ± 0.17, p < 0.05). The innovator product completely disintegrated in 1.25 min. Among all the products, the difference in the disintegration time was insignificant. Overall, the pharmaceutical quality of the tested formulations can be considered as good with regard to the above quality control tests.

**Dissolution Tests**

The dissolution test results ($f_1$, $f_2$, DE, drug release, and %RSD) are shown in Table 2. The rate of dissolution from the dosage forms directly influences the absorption of active pharmaceutical ingredients into the systemic circulation and hence, the bioavailability. In this study, dissolution profiles of the selected generic tablet formulations were evaluated by comparing with that of innovator amlodipine tablet according to biowaiver guidelines of the U.S. FDA and WHO.

**Table 2. In Vitro Dissolution Test Results for Generic (AM) and Innovator Brand Amlodipine Tablets**

<table>
<thead>
<tr>
<th>Dissolution media</th>
<th>Parameters</th>
<th>Products</th>
<th>AM-1</th>
<th>AM-2</th>
<th>AM-3</th>
<th>AM-4</th>
<th>Innovator</th>
</tr>
</thead>
<tbody>
<tr>
<td>pH 1.2 HCl (simulated gastric fluid)</td>
<td>Mean drug release in 30 min ± %RSD</td>
<td></td>
<td>98.4 ± 1.08</td>
<td>97.2 ± 2.08</td>
<td>96.2 ± 1.93</td>
<td>97.8 ± 1.37</td>
<td>97.2 ± 1.16</td>
</tr>
<tr>
<td>DE (%)</td>
<td></td>
<td></td>
<td>83.0</td>
<td>82.8</td>
<td>82.2</td>
<td>82.3</td>
<td>82.2</td>
</tr>
<tr>
<td>pH 4.5 acetate buffer†</td>
<td>Mean drug release in 30 min ± %RSD</td>
<td></td>
<td>97.0 ± 1.49</td>
<td>97.8 ± 1.10</td>
<td>96.6 ± 2.67</td>
<td>96.7 ± 1.55</td>
<td>97.5 ± 1.74</td>
</tr>
<tr>
<td>DE (%)</td>
<td></td>
<td></td>
<td>82.3</td>
<td>81.7</td>
<td>81.2</td>
<td>82.4</td>
<td>81.0</td>
</tr>
<tr>
<td>pH 6.8 phosphate buffer (simulated intestinal fluid)</td>
<td>Mean drug release in 30 min ± %RSD</td>
<td></td>
<td>93.4 ± 3.12</td>
<td>94.5 ± 2.62</td>
<td>92.4* ± 3.16</td>
<td>91.1* ± 3.32</td>
<td>94.9 ± 3.49</td>
</tr>
<tr>
<td>Difference factor ($f_1$)</td>
<td></td>
<td></td>
<td>77</td>
<td>84</td>
<td>75</td>
<td>60</td>
<td>-</td>
</tr>
<tr>
<td>Similarity factor ($f_2$)</td>
<td></td>
<td></td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>-</td>
</tr>
<tr>
<td>DE (%)</td>
<td></td>
<td></td>
<td>78.6</td>
<td>78.0</td>
<td>78.8</td>
<td>75.6</td>
<td>78.2</td>
</tr>
</tbody>
</table>

*Statistically significant difference (p < 0.05) between reference and test products.

†Drug release in pH 1.2 HCl and pH 4.5 buffer is ≥ 85% in 15 min under same dissolution condition; therefore, drug release profiles of the test products were deemed to be equivalent to the innovator brand without statistical treatment.

DE: dissolution efficiency.
Cumulative drug release was calculated using a standard calibration curve prepared by plotting absorbance against concentrations of the calibration standard solutions in the range of 2–20 μg/mL. The calibration standards were prepared in three dissolution media separately (pH 1.2, 4.5, and 6.8) and analyzed by UV-spectrophotometer at 240 nm. Regression analysis was performed, and the correlation coefficient was recorded as 0.999 in pH 1.2 HCl (SGF) and pH 4.5 acetate buffer and 0.998 in phosphate buffer (pH 6.8, SIF). At pH 1.2 and pH 4.5, all products released > 85% of the labeled amount of amlodipine in 15 min; therefore, their dissolution profiles are considered as similar to the innovator product (> 85% release in 15 min) without statistical treatment.

The mean (± SD) percentage of drug release for the generic products in pH 1.2 at 15 min were 96.6% ± 1.43 for AM-1, 94.4% ± 2.35 for AM-2, 93.5 ± 2.11 for AM-3, and 93.3 ± 1.76% for AM-4. In pH 4.5 at 15 min, drug release was 92.1% ± 2.26 for AM-1, 94.4% ± 2.11 for AM-2, 92.9% ± 2.43 for AM-3, and 93.3 ± 2.16 for AM-4. For the innovator product, 94.2% and 92.0% of the labeled amount of amlodipine was released in pH 1.2 and 4.5 at 15 min, respectively.

In pH 6.8, the generic and innovator products released > 85% amlodipine in 30 min. For the generic products, the amount of drug dissolved in pH 6.8 at 30 min was 93.4% ± 3.12 for AM-1, 94.5% ± 2.62 for AM-2, 92.4% ± 3.16 for AM-3, and 91.1% ± 3.32 for AM-4 and 94.9% ± 3.49 for the innovator product. In the pH 6.8 phosphate buffer, the $f_1$ and $f_2$ values indicated that the generic products were similar to the innovator product (Fig. 2). The lowest $f_1$ (1) and highest $f_2$ (84) values were observed for product AM-2, indicating that its dissolution profile is closest to the innovator brand among the tested generic products; product AM-4 exhibited the highest $f_1$ (4) and lowest $f_2$ (60) values.

In an in vitro dissolution study, DE provides another parameter to analyze and compare the drug release of generic and innovator brands based on the AUC; therefore, DE is helpful in the prediction of in vivo drug release. In this study, DE values of test products were within ± 10% limit of that observed for innovator formulation in all three dissolution media (pH 1.2, 4.5, and 6.8). Consequently, the rate of drug release from the generic and innovator amlodipine tablets was similar on the basis of their DE values. The validity of the dissolution results was demonstrated by low %RSD at all time points (≤ 20% at 15 min and ≤ 10% for higher time points). The %RSD of drug dissolved at 30 min for products was in the range of 1.08–3.49%.

Overall, the tested generic products met the WHO BCS class-based biowaiver criteria for in vitro drug dissolution. Therefore, the tested generic products can be considered as equivalent to the innovator product. The efficacy associated with the use of the generic formulations would be comparable to the innovator brand. For the tested products, in vivo bioavailability assessment is not required to ascertain therapeutic effectiveness and interchangeability with the innovator brand in case of unavailability or when cost is a concern.
INTRODUCTION

The USP and the International Conference on Harmonization (ICH) consider drugs according to their aqueous solubility and intestinal permeability for classification into four main groups: Class I (high solubility–high permeability), Class II (low solubility–high permeability), Class III (high solubility–low permeability), and Class IV (low solubility–low permeability). Current regulations do not allow biowaivers of Class II drugs based on their aqueous solubility and intestinal permeability, whereas the ICH defines the limits for in vitro dissolution to support the biorelevance of in vivo performance in comparison to the reference. Other in vitro tests, such as bioavailability (BA) and/or bioequivalence (BE) studies, are required for Class II drugs, in such cases synthetic surfactants may be used to increase drug solubility and dissolution and provide sink conditions due to continuous intestinal absorption of TMX.

For BCS Class II drugs, dissolution can be the rate-limiting step of drug absorption, and therefore synthetic surfactants, such as polysorbate 80, are frequently used in dissolution tests to increase drug solubility and dissolution and provide sink conditions. The pH and composition of the dissolution medium are of great impact on the dissolution process of poorly soluble drugs. Dissolution condition: USP II apparatus, 75 rpm, 500 mL medium at 37 ± 2 ºC.

IMPORTANCE OF TAMOXIFEN

Tamoxifen citrate (TMX) is an example of an anticancer drug that is biowaived based on the dissolution and in vivo performance. Being a BCS Class II weak base, TMX (2-[[4-[(Z)-1,2-diphenylbut-1-enyl]phenox]-N,N dimethylethanamine; 2-hydroxypropane-1,2,3-tricarboxylic acid) (CAS 54965-24-1) was chosen as the model drug for the present study (15). TMX is a selective estrogen receptor modulator in breast cancer treatment, thereby reducing the risk of recurrence and mortality of breast cancer (16). In the present study, in vitro dissolution and to identify the most suitable surfactant medium reflecting the formulation differences and in vivo dissolution of the drug. Being a BCS Class II weak base, TMX (2-[[4-[(Z)-1,2-diphenylbut-1-enyl]phenox]-N,N dimethylethanamine; 2-hydroxypropane-1,2,3-tricarboxylic acid) (CAS 54965-24-1) was chosen as the model drug for the present study (15).

Figure 2. Dissolution profile of generic (AM) and innovator brands of amlodipine tablets in A) pH 1.2 HCl (simulated gastric fluid without enzyme), B) pH 4.5 acetate buffer, and C) pH 6.8 phosphate buffer (simulated intestinal fluid). Dissolution condition: USP II apparatus, 75 rpm, 500 mL medium at 37 ± 2 ºC.
CONCLUSION

Four generic brands of amlodipine tablets (5 mg) were evaluated for their physicochemical properties and found to comply with USP specifications with regard to weight variation, friability, assay, and disintegration time. In vitro drug release of all the generic tablet products was similar to the innovator brand according to WHO bio waiver conditions for formulations containing a BSC class 1 active ingredient. In pH 1.2 HCl and pH 4.5 acetate buffer, ≥ 85% amlodipine released within 15 min; therefore, their dissolution profiles were similar without statistical treatment. In pH 6.8 phosphate buffer, the drug release was ≥ 85% within 30 min, and $f_1$, $f_2$, and DE values indicated similarity of the dissolution profiles. The tested generic formulations were considered to be therapeutically and pharmaceutically equivalent to the innovator product (Norvasc) without in vivo screening. Overall, the products were of good quality and interchangeable with each other.

CONFLICTS OF INTEREST

The authors disclosed no conflicts of interest related to this article.

REFERENCES

The purpose of this study was to investigate the effects of cationic hexadecyltrimethylammonium bromide (CTAB) and nonionic surfactants (polysorbate 80) on the dissolution behaviors of reference and test products. Dissolution tests were performed using USP apparatus II at pH 1.2, 4.5, and 6.8 with and without surfactant. At pH 6.8, the effects of 0.5% (w/v) CTAB and 0.5% (w/v) polysorbate 80 on dissolution were studied.

Tamoxifen (TMX), a Class II weak base, was chosen as the model drug for the present study. 1,2,3-tricarboxylic acid (CAS 54965-24-1) was chosen as the model acid for pH 1.2. TMX is a Class II weak base, indicating that it has limited aqueous solubility. TMX is used to treat breast cancer and to prevent its recurrence in postmenopausal women. It is a key drug in aromatase inhibitor therapy, used to treat breast cancer and to prevent its recurrence in postmenopausal women. TMX is also used in the treatment of endometriosis, where its use can reduce pain and other symptoms.

The in vitro dissolution profile of TMX was evaluated in several surfactant media to determine the effect of surfactants on its dissolution. The dissolution behaviors of the reference and test products were compared to the reference dissolution profile. The effects of surfactants on the dissolution of TMX were studied at pH 1.2, 4.5, and 6.8, with and without surfactant. The results showed that the dissolution of TMX was significantly affected by the presence of surfactants. The dissolution of TMX in the presence of surfactants was much more pronounced compared to pH 1.2. The dissolution of TMX in surfactant media was found to be different from the reference dissolution profile in all surfactant media. Overall, the results of the study indicate that surfactants can significantly affect the dissolution of TMX and that careful selection of surfactant media is required to develop dissolution processes.

References: